Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenues and improvements in net loss for the fiscal year 2025, driven by increased sales and strategic partnerships [5][4]. Financial Highlights - FY 2025 net product revenues increased by 65% to $1.005 million, up from $607.6 thousand in 2024, attributed to rising sales, price increases, and fewer returns [5]. - Gross profit for 2025 was approximately $223.8 thousand, slightly up from $222.8 thousand in 2024, despite inventory write-offs related to short-dated products [5]. - Operating expenses decreased to approximately $8.4 million in 2025 from $10.0 million in 2024, with a notable reduction in R&D costs [5]. - Net loss attributable to common shareholders improved to approximately $7.37 million, or $11.73 per share, compared to a net loss of approximately $7.96 million, or $74.17 per share, in 2024 [5]. Recent Business Highlights - In March 2026, the company announced successful outcomes in its expanded access study for relapsing babesiosis, leading to calls for revised treatment guidelines [5]. - A partnership with GoodRx was established in February 2026 to offer savings on ARAKODA®, expanding its sales footprint to over 70,000 pharmacies [5]. - The company exercised its Florida State University license option for large-scale purification of castanospermine in January 2026, indicating readiness to begin regulatory processes for Australian Chestnut Extract [5]. - A Phase 2 B-FREE Chronic Babesiosis Study commenced in November 2025, aiming to enroll up to 100 patients [5]. - A sponsored research agreement with Tulane University was signed in July 2025 to evaluate tafenoquine's activity against Lyme and Bartonella bacteria [5].

Financial Performance - Total product revenues for 2025 reached $1,005,471, a 65.3% increase from $607,574 in 2024[375] - Gross profit for 2025 was $223,776, slightly up from $222,809 in 2024, indicating stable profitability despite increased revenues[375] - The net loss attributed to 60 Degrees Pharmaceuticals, Inc. for 2025 was $7,365,158, compared to a loss of $7,947,107 in 2024, representing a 7.3% improvement[376] - For the year ended December 31, 2025, the net loss was $7,368,325, compared to a net loss of $7,955,663 for the year ended December 31, 2024, representing a decrease of approximately 7.4%[385] - The total loss before income taxes for 2025 was $(7,368,325), a slight improvement from $(7,955,663) in 2024[517] Expenses and Costs - Research and development expenses decreased to $2,106,156 in 2025 from $4,986,526 in 2024, reflecting a strategic shift in resource allocation[375] - Total operating expenses for 2025 were $8,385,979, down from $10,011,761 in 2024, showing a reduction of approximately 16.3%[375] - Share-based compensation expense for the year ended December 31, 2025, was $279,873, significantly higher than $32,767 in 2024, reflecting an increase of over 754%[385] - The depreciation expense increased to $43,324 in 2025 from $11,726 in 2024, showing a rise of approximately 269%[385] - Operating lease costs for the years ended December 31, 2025, and 2024 were $20,350 and $28,867, respectively[538] Assets and Liabilities - Cash and cash equivalents decreased to $1,510,065 in 2025 from $1,659,353 in 2024, indicating a need for improved liquidity management[373] - Total assets declined to $5,366,211 in 2025 from $5,759,345 in 2024, a decrease of approximately 6.8%[373] - Total liabilities increased to $1,986,795 in 2025 from $1,804,339 in 2024, marking an increase of about 10.1%[373] - The accumulated deficit grew to $47,893,115 in 2025 from $40,527,957 in 2024, highlighting ongoing financial challenges[373] - The total shareholders' equity as of December 31, 2025, was $3,379,416, a decrease from $3,955,006 as of December 31, 2024, indicating a decline of about 14.6%[381] Cash Flow - The company reported a net cash used in operating activities of $6,849,022 for the year ended December 31, 2025, compared to $5,648,088 for the previous year[392] - The company had net cash provided by financing activities of $6,437,691, a decrease from $7,053,571 in the prior year[392] - The company’s cash flows from operating activities showed a net loss of $7,368,325 for 2025, which is an improvement compared to the previous year's loss of $7,955,663[385] Stock and Equity - The weighted average number of common shares outstanding increased to 670,211 in 2025 from 113,665 in 2024, reflecting changes in capital structure[376] - The Company has authorized 150,000,000 shares of common stock and 1,000,000 shares of preferred stock, with 1,163,142 shares of common stock and 76,480 shares of Series A Preferred Stock issued and outstanding as of December 31, 2025[469] - The Company executed a 1:12 Reverse Stock Split on August 12, 2024, reducing outstanding shares from 21,219,937 to 1,768,337[470] - Following a 1:5 Reverse Stock Split on February 24, 2025, the number of outstanding shares decreased from 7,364,554 to 1,472,891[471] - A 1:4 Reverse Stock Split was implemented on January 20, 2026, further reducing shares from 5,436,441 to 1,359,091[472] Revenue Recognition - The Company recognizes revenue from product sales when control is transferred, with the majority of revenues coming from sales of its Arakoda™ product[433] - The Company recognizes research revenues associated with its contract with the US Army Medical Materiel Development Activity, with revenue recognized when eligible costs are incurred[434] Inventory and Assets Management - The company reported a change in inventory reserve of $251,677 for the year ended December 31, 2025, compared to no change in 2024, indicating a strategic adjustment in inventory management[385] - As of December 31, 2025, the total inventory amounted to $656,924, an increase from $442,764 in 2024, with raw materials valued at $75,662, work in process at $446,957, and finished goods at $385,982[464] Future Outlook and Risks - The company plans to fund operations through third-party debt, private placements, and stock issuances until achieving profitability[395] - The company is subject to significant risks, including the ability to obtain regulatory approvals and competition in the biopharmaceutical industry[390] - The company’s future results are uncertain, and there is substantial doubt about its ability to continue as a going concern for one year from the issuance of the financial statements[396] Tax and Deferred Assets - The Company has established a full valuation allowance against its net deferred tax assets as of December 31, 2025, indicating it is not likely to recognize these benefits[421] - Deferred tax assets increased to $8,196,960 in 2025 from $5,984,119 in 2024, primarily due to an increase in net operating loss carry-forwards[520] - The Company had U.S. federal and state net operating loss carryforwards of approximately $17,028,834 and $17,026,834 respectively as of December 31, 2025, compared to $9,235,194 and $9,234,194 in 2024[521] Subsequent Events - The Company has evaluated subsequent events through March 30, 2026, prior to the issuance of the financial statements[457] - The Company is currently assessing the impact of several recently issued Accounting Standards Updates (ASUs) on its financial statement disclosures, including ASU 2023-07 and ASU 2023-09[459][460]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. has submitted a New Dietary Ingredient Notification for Australian Chestnut Extract to the FDA, with a marketing opportunity expected post-May 25, 2026, if no objections arise [1][9] Group 1: Company Developments - The company has signed an option agreement with Florida State University (FSU) to license rights related to new capsule formulation methods for Australian Chestnut Extract, building on a previous license for large-scale purification of Castanospermine [2][9] - 60 Degrees Pharmaceuticals specializes in developing medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA® (tafenoquine), in 2018, which is available in the U.S. and Australia [6] Group 2: Product Information - Australian Chestnut Extract is derived from the seeds of Castanospermum australe, with castanospermine as its dominant molecular constituent [3] - Scientific literature indicates that castanospermine can modulate carbohydrate metabolism at low doses and has shown potential in impacting disease outcomes through immunomodulation in animal models [4] - Castanospermine is a metabolite of celgosivir, previously evaluated in clinical trials for HIV and Hepatitis C, suggesting its safety and efficacy at achievable doses in humans [5]

Core Viewpoint - 60 Degrees Pharmaceuticals Inc. experienced significant stock volatility, with a notable decline following a substantial increase due to positive trial results for its babesiosis treatment [1][2]. Group 1: Stock Performance - Shares of 60 Degrees Pharmaceuticals fell by 9.6%, closing at $2.91, after a previous surge of nearly 48% due to successful trial results [1]. - During premarket trading, shares were down 7.90% at $2.68 [6]. Group 2: Clinical Trial Results - The company's trial for babesiosis demonstrated a nearly 100% cure rate in immunosuppressed patients when tafenoquine was included in their treatment regimen [2]. - Tafenoquine, marketed as ARAKODA, is currently approved for malaria prophylaxis but is not yet FDA-approved for treating babesiosis [3]. Group 3: Partnerships and Market Position - In January, the company partnered with Runway Health to enhance access to ARAKODA through a telehealth platform for travelers [4]. - Analyst consensus indicates a Buy rating for the stock, with an average price target of $17.60, despite current weak momentum [5].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Tilly's, Inc. (TLYS) is up 63% at $2.63 - Bumble Inc. (BMBL) is up 25% at $3.55 - Petco Health and Wellness Company, Inc. (WOOF) is up 16% at $2.80 - Lightwave Logic, Inc. (LWLG) is up 15% at $5.82 - TMD Energy Limited (TMDE) is up 15% at $2.65 - Laird Superfood, Inc. (LSF) is up 11% at $2.77 - Build-A-Bear Workshop, Inc. (BBW) is up 10% at $48.20 - AIFU Inc. (AIFU) is up 9% at $2.09 - BitFuFu Inc. (FUFU) is up 7% at $2.21 - Mexco Energy Corporation (MXC) is up 6% at $12.59 [3] Premarket Losers - Netskope, Inc. (NTSK) is down 15% at $10.25 - FreeCast, Inc. (CAST) is down 14% at $6.82 - Paranovus Entertainment Technology Ltd. (PAVS) is down 14% at $1.95 - ESGL Holdings Limited (OIO) is down 11% at $3.31 - Acurx Pharmaceuticals, Inc. (ACXP) is down 10% at $5.39 - UiPath, Inc. (PATH) is down 7% at $11.45 - Aptera Motors Corp. (SEV) is down 7% at $3.19 - HighPeak Energy, Inc. (HPK) is down 5% at $5.55 - 60 Degrees Pharmaceuticals, Inc. (SXTP) is down 5% at $3.06 - Bit Origin Ltd (BTOG) is down 5% at $2.59 [4]

Core Viewpoint - 60 Degrees Pharmaceuticals has reported a 100% cure rate for babesiosis in three immunosuppressed patients treated with tafenoquine, suggesting significant potential for this treatment in severe cases of the disease [1][10]. Study Details - The expanded use trial is an open-label, multi-site study assessing the safety and efficacy of the ARAKODA regimen (tafenoquine combined with atovaquone and other treatments) for patients with relapsing babesiosis who have not responded to standard treatments [2]. - Tafenoquine treatment lasts up to one year, requiring two consecutive negative PCR tests for Babesia parasites and resolution of symptoms for a patient to be considered cured [3]. - The study protocol includes follow-up visits to assess parasite infection status using highly sensitive tests, including an FDA-approved RNA amplification test [3]. Previous Research - A Yale study indicated a 100% treatment success rate in four patients when tafenoquine was added to a standard regimen, while a fifth patient did not achieve success due to not sustaining the treatment [4]. - In total, seven patients from both the Yale study and the Company's study showed a near 100% cure rate when tafenoquine was included in their treatment regimen [6]. Implications for Treatment Guidelines - Given the high cure rate associated with tafenoquine, the Company believes it is timely to review existing treatment guidelines for babesiosis [7]. Disease Context - Babesiosis is a serious tick-borne illness that can be life-threatening, particularly in elderly and immunosuppressed patients, with rising incidence rates and no FDA-approved treatments or vaccines currently available [8]. Product Information - Tafenoquine, marketed as ARAKODA, is currently approved for malaria prophylaxis but not for babesiosis treatment [9].

Core Insights - 60 Degrees Pharmaceuticals Inc. has partnered with GoodRx to improve the affordability and accessibility of ARAKODA, the only FDA-approved once-weekly malaria prevention medication in the US [1][6] - The partnership allows eligible patients to save up to 30% on ARAKODA at over 70,000 pharmacies nationwide [1] Company Strategy - This initiative is part of the company's strategy to reduce out-of-pocket costs for international travelers going to malaria-endemic regions [2] - ARAKODA was developed by the Walter Reed Army Institute of Research and has a long terminal half-life of approximately 16 days, supporting its weekly dosing schedule [2] Treatment Regimen - The treatment involves a three-day loading phase before travel, followed by weekly doses during the stay and a final dose upon return [3] - The drug is a significant advancement in malaria prevention, a life-threatening disease transmitted by the Anopheles mosquito [3] Safety Protocols - The company emphasizes strict safety protocols, requiring G6PD deficiency testing for all patients before prescription to mitigate the risk of hemolytic anemia [3] Company Overview - 60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases in the US, specifically offering ARAKODA for malaria prevention [4]

Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with GoodRx to provide savings of up to 30% on ARAKODA (tafenoquine) for eligible consumers [1][10] - ARAKODA is the only FDA-approved, once-weekly malaria prevention medication available in the U.S. market, making it a preferred choice for travelers to malaria-endemic regions [2][6] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [19] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [19] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in patients aged 18 and older and has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7][8] - The medication was discovered by the Walter Reed Army Institute of Research and has undergone extensive safety assessments in clinical trials [5][6] Partnership Details - The collaboration with GoodRx aims to lower out-of-pocket costs for patients and expand the marketing reach of ARAKODA, making it accessible at over 70,000 pharmacies nationwide [10][4] - Eligible patients can access a low self-pay price for ARAKODA through GoodRx starting February 2, 2026 [4][10]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. is initiating the regulatory process to gain access to the U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses [1][5]. Group 1: Company Developments - The company has exercised its option with Florida State University to negotiate an exclusive license for large-scale purification techniques to extract castanospermine from Australian Chestnut seeds [1]. - Since signing the option agreement in April 2025, the company has conducted safety testing on Australian Chestnut Extract and developed various prototype capsule formulations for oral delivery [5]. - 60 Degrees Pharmaceuticals specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6]. Group 2: Product Information - Castanospermum australe, the source of castanospermine, is primarily found in Queensland and New South Wales, Australia, as well as in Florida, Hawaii, and California [2]. - Castanospermine has been shown to modulate carbohydrate metabolism and impact disease outcomes in animal models through immunomodulation [3]. - It is also a metabolite of celgosivir, which has been evaluated in clinical trials against HIV and Hepatitis C, suggesting castanospermine's safety and activity against similar pharmacological targets [4].

Company Performance - Spring Valley Acquisition Corp. III Warrants (NASDAQ:SVACW) experienced a significant price increase of 294.23%, reaching $2.05, potentially driven by speculative trading or news related to their energy and decarbonization operations [1][6] - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) saw its stock price rise by 144.5% to $4.89, likely benefiting from positive clinical trial developments or regulatory approvals, despite a 1-4 reverse stock split leading to a 2.4% decline ahead of the event [2] - IO Biotech, Inc. (NASDAQ:IOBT) had a stock price increase of 102.12%, reaching $0.41, with investor optimism possibly fueled by its focus on immune-modulating cancer therapies and exploration of strategic alternatives [3][6] - Namib Minerals Warrants (NASDAQ:NAMMW) recorded an 88.68% increase to $0.34, influenced by its involvement in gold and critical green metals production and exploration, while Namib Minerals Ordinary Shares (NASDAQ:NAMM) rose by 77.47% to $4.01, possibly due to favorable mining outcomes or strategic acquisitions [4] Market Dynamics - The recent stock price movements highlight the dynamic nature of the market, where company developments, industry trends, and investor sentiment play crucial roles in influencing stock prices [5]